84. Sarcoidosis Clinical trials / Disease details
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03793439 (ClinicalTrials.gov) | May 15, 2019 | 2/1/2019 | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Sarcoidosis, Pulmonary;Sarcoidosis Lung;Sarcoidosis | Drug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Diagnostic Test: Spirometry;Genetic: RNA Sequencing;Diagnostic Test: Laboratory testing;Drug: Corticosteroid;Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extension | Oregon Health and Science University | Pfizer | Recruiting | 18 Years | 89 Years | All | 5 | Phase 1 | United States |
| 2 | NCT03910543 (ClinicalTrials.gov) | April 11, 2019 | 4/4/2019 | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Cutaneous Sarcoidosis;Granuloma Annulare | Drug: Tofacitinib 5 mg twice daily | Yale University | Pfizer | Completed | 18 Years | N/A | All | 15 | Phase 1 | United States |